General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations

BJU International

Volumn 110, Issue 1, 2012, Pages 24-27

  Wong, Lih Ming ^a   Johnston, Richard ^a   Sharma, Naomi ^a   Shah, Nimish C ^a   Warren, Anne Y ^a   Neal, David E ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Active surveillance; Guidelines; Low risk; NICE; Prostate cancer; Radical prostatectomy

Indexed keywords

ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; COMPUTER ASSISTED SURGERY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; ROBOTICS; SEMINAL VESICLE;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84862295270     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10730.x     Document Type: Article

References (21)

1. National Institute for Health and Clinical Excellence. NICE clinical guideline 58, Prostate cancer: diagnosis and treatment. 2008. Available at: http://www.nice.org.uk/nicemedia/pdf/CG58NICEGuideline.pdf. Accessed October 2011
2. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74 (Pubitemid 28445094)
3. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
4. Hugosson J, Carlsson S, Aus G et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-32
5. Pashayan N, Duffy SW, Pharoah P et al. Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer 2009; 100: 1198-204
6. Bangma CH, Roemeling S, Schroder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 2007; 25: 3-9
7. Bill-Axelson A, Holmberg L, Filen F et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100: 1144-54
8. Draisma G, Etzioni R, Tsodikov A et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009; 101: 374-83
9. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostatespecific antigen failure. J Clin Oncol 2005; 23: 4975-9 (Pubitemid 46224003)
10. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 2010; 46: 3095-101
11. Donovan J, Mills N, Smith M et al. Quality improvement report: improving design and conduct of randomised trials by embedding them in qualitative research: protecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. BMJ 2002; 325: 766-70
12. Dall ' Era MA, Cooperberg MR, Chan JM et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008; 112: 1650-9
13. Klotz L. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer. Nat Clin Pract Urol 2005; 2: 136-42 (Pubitemid 40812444)
14. Parker C. A more selective approach to prostate biopsy could be a safe and effective form of prostate cancer 'prevention'. BJU Int 2007; 100: 488-90 (Pubitemid 47205481)
15. Melia J, Moss S, Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 2004; 94: 51-6 (Pubitemid 38980308)
16. Parker C, Muston D, Melia J, Moss S, Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006; 94: 1361-8 (Pubitemid 43772267)
17. Moore AL, Dimitropoulou P, Lane A et al. Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. BJU Int 2009; 104: 1592-8
18. Bartsch G, Horninger W, Klocker H et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417-24 (Pubitemid 32816361)
19. Cancer Research UK. Prostate cancer -UK incidence statistics. Available at: http://www.cancerresearchuk.org. Accessed October 2011
20. Kattan MW, Eastham JA, Wheeler TM et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 1792-7 (Pubitemid 37254930)
21. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2009; 28: 126-31